Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. The Company is led by an experienced team of researchers and business executives who have developed and commercialized technologies, launched products, driven sales, negotiated partnerships, and led a number of companies from start up to liquidity events.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/16/17 | $6,000,000 | Series B |
Connecticut Innovations HighCape Partners | undisclosed |
| 03/10/21 | $25,000,000 | Series B |
Elm Street Ventures HighCape Partners | undisclosed |
